Alnylam Pharmaceuticals
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.About ALNY
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference.
ALNY Key Statistics
ALNY News
Goldman Sachs analysts removed Alnylam (ALNY) from the firm’s US Conviction List as part of its monthly update. Elevate Your Investing Strategy: Take advantag...
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface...
Alnylam Pharmaceuticals (ALNY) achieved profitability over the past year, with average annual earnings growth of 27.5% over the last five years. Looking ahead,...
Analyst ratings
74%
of 31 ratingsMore ALNY News
Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...
Alnylam Pharmaceuticals ( (ALNY) ) has released its Q3 earnings. Here is a breakdown of the information Alnylam Pharmaceuticals presented to its investors. Elev...
Alnylam Pharma, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the...
Alnylam Pharmaceuticals, Inc. recently reported third quarter 2025 results, posting revenues of US$1.25 billion and net income of US$251.08 million, a substanti...
Analyst Joseph Stringer from Needham maintained a Buy rating on Alnylam Pharma and increased the price target to $520.00 from $478.00. Elevate Your Investing St...
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) stock is trading lower after the company reported third-quarter earnings. Alnylam also said that it received a subpo...
Alnylam easily beat Wall Street's third-quarter forecasts on the back of its biggest moneymaker, Amvuttra. Alnylam stock, which has already doubled in 2025, cou...
